Leerink Partners正式启动对Collegium Pharmaceutical, Inc.(简称:Collegium Pharmaceutical)的覆盖研究,首次给予其“跑赢大盘”评级,并设定目标股价为45美元。
Leerink Partners正式启动对Collegium Pharmaceutical, Inc.(简称:Collegium Pharmaceutical)的覆盖研究,首次给予其“跑赢大盘”评级,并设定目标股价为45美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.